<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00470340</url>
  </required_header>
  <id_info>
    <org_study_id>P051062</org_study_id>
    <nct_id>NCT00470340</nct_id>
  </id_info>
  <brief_title>Chemotherapy or Not, Following Complete Treatment of Hepatic Cancer in Cirrhotic Patients</brief_title>
  <acronym>GEMOXIAL</acronym>
  <official_title>Arterial LIPIODOLISED Chemotherapy Versus Systemic Chemotherapy With Gemcitabine Plus Oxaliplatin (GEMOX) Versus no Treatment Following Surgical Resection or Local Ablation of Hepatocellular Carcinoma in Cirrhotic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Besides liver transplantation, the curative treatment of primary hepatic cancer with&#xD;
      cirrhosis remains the surgical resection. Radiofrequency or cryotherapy currently allow local&#xD;
      ablation of small cancer, with very good results. However, all these treatments are followed&#xD;
      by high rates of recurrence (50 - 70% at 5 years). Then, it seems essential to associate to&#xD;
      the surgical resection or to the local ablation as &quot;adjuvant&quot; treatment, in order to prevent&#xD;
      or to decrease the rate of recurrence. However, no evidence supports this attitude.&#xD;
      Therefore, following curative treatment of primary hepatic cancer with cirrhosis, we propose&#xD;
      to compare treated to untreated patients. Postoperative treatment means either intra-arterial&#xD;
      chemotherapy or systemic chemotherapy. The main criterion of the study is time of survival&#xD;
      without recurrence. The main secondary objective is the safety.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The best treatment for hepatocellular carcinoma (HCC) with cirrhosis, currently is liver&#xD;
      transplantation because treating the cancer and the causal disease. For the majority of&#xD;
      patients, transplantation is not proposed, and the curative treatment remains the surgical&#xD;
      resection. Radiofrequency or cryotherapy currently allows local destruction (or ablation) of&#xD;
      the small HCC, with results that seem equivalent to the surgical resection. These last&#xD;
      techniques increase the therapeutic possibilities in the presence of hepatic insufficiency.&#xD;
      However, all these treatments are followed by high rates of recurrence (50 - 70% at 5 years&#xD;
      and close to 100% at 10 years). The development of tumoral nodules, undetected at the time of&#xD;
      the curative treatment, or the occurrence of new HCC, under the effects of the cirrhotic&#xD;
      process or viral genomic modifications explain these disappointing results. Therefore, it&#xD;
      seems essential to associate an adjuvant treatment to the surgical resection or the local&#xD;
      destruction. Intra-arterial chemotherapy with or without embolisation is a largely evaluated&#xD;
      therapeutic approach whose results are contradictory. Several retrospective studies, seem&#xD;
      nevertheless to show a benefit of this treatment in adjuvant situation. Systemic chemotherapy&#xD;
      for a long time regarded as ineffective, currently has a renewed interest due to the use of&#xD;
      new drugs like gemcitabine and oxaliplatin (GEMOX regimen). This regimen showed a certain&#xD;
      effect in a phase II study in advanced forms of HCC with cirrhosis. We propose to test by a&#xD;
      prospective randomized multicentric phase III study, the effectiveness of an adjuvant&#xD;
      treatment by systemic chemotherapy or intra-arterial LIPIODOLISED chemotherapy (CIAL), after&#xD;
      surgery or complete local destruction of HCC. Three groups will be compared: a group of&#xD;
      untreated patients (n=109), a group of patients treated by intra-arterial chemotherapy (CIAL&#xD;
      = cisplatin 75 mg + lipiodol 10 ml; 3 courses every 6 weeks)(n=77) and a group of patients&#xD;
      treated by systemic chemotherapy (GEMOX= day 1: gemcitabine 1000 mg/m² iv within 100 min; day&#xD;
      2: oxaliplatin 100 mg/m² iv within 2h; 8 courses every 2 weeks, d1 = d14)(n=77). Selection&#xD;
      and randomisation are planned 4-8 weeks following complete treatment of the HCC. Identical&#xD;
      follow up for the 3 groups includes clinical, biological, morphological exams every 3 months&#xD;
      for 2 years, then every 6 months for 3 years. The main criterion of the study is survival&#xD;
      without recurrence. The secondary objectives are the global survival, the safety and an&#xD;
      estimate of the costs of the various treatments. The awaited results are 1) to demonstrate&#xD;
      the effectiveness of at least one of these adjuvant treatment following complete treatment of&#xD;
      HCC in cirrhotic patients and 2) to determine the best adjuvant treatment. Estimated&#xD;
      inclusion time is 2 years, with an analysis of the principal criterion at 3 years. Follow-up&#xD;
      of 5 years is envisaged for each patient, leading to a 7 years duration study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    during the study&#xD;
  </why_stopped>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival without recurrence at 2 years</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morbidity and mortality following adjuvant treatment</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">263</enrollment>
  <condition>Liver Neoplasms</condition>
  <condition>Liver Cirrhosis</condition>
  <condition>Carcinoma, Hepatocellular</condition>
  <condition>Recurrence</condition>
  <condition>Neoplasm Recurrence, Local</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin, gemcitabine, cisplatin, lipiodol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin, gemcitabine, cisplatin, lipiodol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin, gemcitabine, cisplatin, lipiodol</intervention_name>
    <description>Oxaliplatin, gemcitabine, cisplatin, lipiodol</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hepatocellular carcinoma (histology or Barcelona criteria) curatively treated by&#xD;
             surgical resection or by radiofrequency or by cryotherapy&#xD;
&#xD;
          -  Evidence of liver cirrhosis (clinical, biological, endoscopic or histological&#xD;
             criteria)&#xD;
&#xD;
          -  Morphological evaluation 4 to 6 weeks following curative treatment&#xD;
&#xD;
          -  No evidence of local or distant disease on the morphological evaluation&#xD;
&#xD;
          -  Absence of peritoneal or lymph node metastasis&#xD;
&#xD;
          -  Absence of pre- or per-operative macroscopic tumoral thrombus&#xD;
&#xD;
          -  Minimal free margin of 5 mm following pathological exam&#xD;
&#xD;
          -  ALPHAAFOETOPROTEINE level of less than 4 normal values or decreased by 50%, 4 to 6&#xD;
             weeks following curative treatment&#xD;
&#xD;
          -  Biological criteria, 2 weeks before treatment as follow:&#xD;
&#xD;
               -  neutrophilic polymorphonuclear &gt; 1500/mm3,&#xD;
&#xD;
               -  platelets &gt; 100 000/mm3,&#xD;
&#xD;
               -  total bilirubin &lt; 25 mmol/l (1.46 mg/dl),&#xD;
&#xD;
               -  creatinin &lt; 1.5 x normal value&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) equal to 0 or 1&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks&#xD;
&#xD;
          -  Absence of sensitive neuropathy at inclusion time&#xD;
&#xD;
          -  Health insurance coverage&#xD;
&#xD;
          -  Efficient contraceptive method if applicable&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Curative treatment performed 10 weeks or more before the beginning of adjuvant&#xD;
             treatment&#xD;
&#xD;
          -  Contraindication to an angiography or hepatic artery thrombosis or portal thrombosis.&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Concomitant involvement to any clinical trial&#xD;
&#xD;
          -  Decompensate cirrhosis and Child-Pugh score ≥ 8 or clinical ascitis.&#xD;
&#xD;
          -  Cancer of the Liver Italian Program (C.L.I.P.) score ≥ 2&#xD;
&#xD;
          -  Heart or lung insufficiency&#xD;
&#xD;
          -  Other cancer not considered as definitively cured&#xD;
&#xD;
          -  Creatinin clearance &lt; 30 ml/min&#xD;
&#xD;
          -  Recurrence of HCC less than 12 months following any last treatment&#xD;
&#xD;
          -  Any radiotherapy during the 4 weeks before inclusion&#xD;
&#xD;
          -  Known sensitivity to any drug of this protocol&#xD;
&#xD;
          -  Immunodeficiency (HIV+, transplanted patient)&#xD;
&#xD;
          -  Inability of follow up&#xD;
&#xD;
          -  Impossibility of clear understanding of the protocol for no french speaking patient&#xD;
&#xD;
          -  Patient under legal protection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Savier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urc La Pitie Salpetriere,</name>
      <address>
        <city>Poissy</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <study_first_submitted>May 4, 2007</study_first_submitted>
  <study_first_submitted_qc>May 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2007</study_first_posted>
  <last_update_submitted>May 4, 2011</last_update_submitted>
  <last_update_submitted_qc>May 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Isabelle Brindel</name_title>
    <organization>Department of Clinical Research of developpement</organization>
  </responsible_party>
  <keyword>Recurrence</keyword>
  <keyword>Neoplasm Recurrence, Local</keyword>
  <keyword>Liver</keyword>
  <keyword>Liver Neoplasms</keyword>
  <keyword>Liver Cirrhosis</keyword>
  <keyword>Carcinoma, Hepatocellular</keyword>
  <keyword>Iodized Oil</keyword>
  <keyword>gemcitabine [Substance Name]</keyword>
  <keyword>oxaliplatin [Substance Name]</keyword>
  <keyword>gemcitabine-oxaliplatin regimen [Substance Name]</keyword>
  <keyword>Randomized Controlled Trials</keyword>
  <keyword>Multicenter Studies</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Injections, Intra-Arterial</keyword>
  <keyword>Injections, Intravenous</keyword>
  <keyword>Chemotherapy, Adjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Neoplasm Recurrence, Local</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Ethiodized Oil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

